A recent meta-analysis concluded that plasma exchange is the most effective intervention for thrombotic thrombocytopenic purpura and that plasma manipulation offers no additional benefit over simple supportive therapy in hemolytic uremic syndrome. These findings must be interpreted with great caution, as response to treatment depends on the underlying disease etiology.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Ruggenenti, P., Noris, M. & Remuzzi, G. Thrombotic microangiopathies. In Therapy in Nephrology and Hypertension: A Companion to Brenner and Rector's The Kidney 3rd edn (ed. Wilcox, C. S.) 294–312 (Saunders, Philadelphia, 2008).
Michael, M., Elliott, E. J., Craig, J. C., Ridley, G. & Hodson, E. M. Interventions for hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: a systematic review of randomized controlled trials. Am. J. Kidney Dis. 53, 259–272 (2008).
Ruggenenti, P., Galbusera, M., Cornejo, R. P., Bellavita, P. & Remuzzi, G. Thrombotic thrombocytopenic purpura: evidence that infusion rather than removal of plasma induces remission of the disease. Am. J. Kidney Dis. 21, 314–318 (1993).
Davin, J. C., Strain, L. & Goodship, T. H. Plasma therapy in atypical haemolytic uremic syndrome: lessons from a family with a factor H mutation. Pediatr. Nephrol. 23, 1517–1521 (2008).
Nathanson, S., Frémeaux-Bacchi, V. & Deschênes, G. Successful plasma therapy in the hemolytic uremic syndrome with factor H deficiency. Pediatr. Nephrol. 16, 554–556 (2001).
Caprioli, J. et al. Genetics of HUS: the impact of MCP, CFH and IF mutations on clinical presentation, response to treatment, and outcome. Blood 108, 1267–1279 (2006).
Sellier-Leclerc, A. L, Fremeaux-Bacchi, V., Dragon-Durey, M. A., Macher, M. A. & Niaudet, P. Differential impact of complement mutations on clinical characteristics in atypical hemolytic uremic syndrome. J. Am. Soc. Nephrol. 18, 2390–2400 (2007).
Acknowledgements
Our work is partially supported by grants from Fondazione ART per la Ricerca sui Trapianti (Milan, Italy), from Fondazione Aiuto Ricerca Malattie Rare (ARMR) and from Istituto Superiore di Sanit. We are greatly indebted to Dr Arrigo Schieppati for the critical reading and editing of this manuscript.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Noris, M., Remuzzi, G. What not to learn from a meta-analysis. Nat Rev Nephrol 5, 186–188 (2009). https://doi.org/10.1038/nrneph.2009.28
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2009.28
This article is cited by
-
Deficiency of CFHR plasma proteins and autoantibody positive hemolytic uremic syndrome: treatment rationale, outcomes, and monitoring
Pediatric Nephrology (2021)
-
Dual RAS blockade—controversy resolved
Nature Reviews Nephrology (2013)
-
Do meta-analyses in nephrology change the way we treat patients?
Kidney International (2010)
